CytoDyn Appoints Scott A. Kelly, M.D., as Chief Medical Officer and Head of Business Development
April 13, 2020 6:00am EDT
Company expands its management team to accelerate the evaluation of leronlimab for multiple clinical indications, including COVID-19, 23 different Cancers, GvHD, NASH and MS
VANCOUVER, Washington, April 13, 2020 (GLOBE NEWSWIRE) -- The Board of Directors (the “Board”) of CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, appointed Scott A. Kelly, M.D. as Chief Medical Officer and Head of Business Development for the Company.
Dr. Kelly, a director since April 2017, has served as the Company’s Chairman of the Board since December 2018 and will retain his position as Chairman. Dr. Kelly has served at Atlanta-based Resurgens Orthopaedics since 2002, including as Director of the Safety Council since 2013 and as Medical Director of the Resurgens Orthopaedics' Spine Center since 2007. Dr. Kelly received his BA in Psychology from Emory University, his medical doctorate from Medical College of Georgia and completed his medical residency at Emory University.
Dr. Kelly, commented, “I have decided to leave clinical medicine to focus on CytoDyn. Dr. Nader Pourhassan has done an excellent job in expanding the pipeline of opportunities for leronlimab and navigating the regulatory pathways toward approval. This is a tremendous opportunity to become more deeply involved with the management team to advance the multi-pathway evaluation of leronlimab. Recent studies indicate leronlimab has significant potential therapeutic benefits for patients suffering from COVID-19, HIV, metastatic triple-negative breast cancer, immunologic diseases such as graft-versus-host disease, NASH, and several other indications. I look forward to pursuing these opportunities for patients, and the evaluation of partnerships that align with the vision of CytoDyn and its shareholders.”
Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn said, “We are honored Dr. Kelly agreed to increase his commitment to the Company. Dr. Kelly has been instrumental in progressing CytoDyn to explore the many opportunities for leronlimab and to continue to expand its pipeline. With Dr. Kelly as part of our team, I am very confident many strong achievements will be realized in an expedited fashion for our Company and its shareholders.”
April 13, 2020 6:00am EDT
Company expands its management team to accelerate the evaluation of leronlimab for multiple clinical indications, including COVID-19, 23 different Cancers, GvHD, NASH and MS
VANCOUVER, Washington, April 13, 2020 (GLOBE NEWSWIRE) -- The Board of Directors (the “Board”) of CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, appointed Scott A. Kelly, M.D. as Chief Medical Officer and Head of Business Development for the Company. Dr. Kelly, a director since April 2017, has served as the Company’s Chairman of the Board since December 2018 and will retain his position as Chairman. Dr. Kelly has served at Atlanta-based Resurgens Orthopaedics since 2002, including as Director of the Safety Council since 2013 and as Medical Director of the Resurgens Orthopaedics' Spine Center since 2007. Dr. Kelly received his BA in Psychology from Emory University, his medical doctorate from Medical College of Georgia and completed his medical residency at Emory University.
Dr. Kelly, commented, “I have decided to leave clinical medicine to focus on CytoDyn. Dr. Nader Pourhassan has done an excellent job in expanding the pipeline of opportunities for leronlimab and navigating the regulatory pathways toward approval. This is a tremendous opportunity to become more deeply involved with the management team to advance the multi-pathway evaluation of leronlimab. Recent studies indicate leronlimab has significant potential therapeutic benefits for patients suffering from COVID-19, HIV, metastatic triple-negative breast cancer, immunologic diseases such as graft-versus-host disease, NASH, and several other indications. I look forward to pursuing these opportunities for patients, and the evaluation of partnerships that align with the vision of CytoDyn and its shareholders.”
Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn said, “We are honored Dr. Kelly agreed to increase his commitment to the Company. Dr. Kelly has been instrumental in progressing CytoDyn to explore the many opportunities for leronlimab and to continue to expand its pipeline. With Dr. Kelly as part of our team, I am very confident many strong achievements will be realized in an expedited fashion for our Company and its shareholders.”
8
